Abelacimab

Results from the INFINITY-SWEDEHEART trial showed that Elixir Medical’s drug-eluting coronary implant was noninferior to a drug-eluting stent for target lesion failure at 1 year.

Patients with atrial fibrillation needing stroke prevention assigned to abelacimab had very low rates of bleeding during invasive procedures, according to new data from the AZALEA-TIMI 71 trial.

Direct oral anticoagulants have become the standard of care for stroke prevention in patients with atrial fibrillation, among other indications, but factor XI/XIa inhibitors may have the potential to usurp them due to safety profiles.

PHILADELPHIA — In a phase 2b trial, abelacimab, a novel factor XI inhibitor, drastically reduced bleeding compared with rivaroxaban in patients with atrial fibrillation requiring stroke prevention.

Healio and Cardiology Today have compiled a list of the top news in cardiology of September 2023.

Anthos Therapeutics announced that the phase 2 AZALEA-TIMI 71 study was stopped early due to an “overwhelming reduction” in bleeding in patients with atrial fibrillation at high risk for stroke taking abelacimab vs. rivaroxaban.

Anthos Therapeutics announced abelacimab, a fully human monoclonal antibody inhibiting factor XI, received fast track designation from the FDA for an indication to prevent stroke and systemic embolism in patients with atrial fibrillation.

The FDA granted fast track designation to abelacimab for treatment of cancer-associated thrombosis, according to a press release from the agent’s manufacturer.

A single IV dose of the factor XI monoclonal antibody abelacimab appeared superior to daily enoxaparin for preventing venous thromboembolism after total knee arthroplasty, according to randomized study results.